PMID- 38323999 OWN - NLM STAT- Publisher LR - 20240207 IS - 1528-1132 (Electronic) IS - 0009-921X (Linking) DP - 2024 Feb 6 TI - Does the Combination of Platelet-rich Plasma and Supervised Exercise Yield Better Pain Relief and Enhanced Function in Knee Osteoarthritis? A Randomized Controlled Trial. LID - 10.1097/CORR.0000000000002993 [doi] AB - BACKGROUND: Knee osteoarthritis is a leading cause of disability with substantial healthcare costs, and efficient nonsurgical treatment methods are still needed. Platelet-rich plasma (PRP) injections and exercise therapy are used frequently in clinical practice. Whether PRP or PRP combined with exercise is more effective than exercise alone is unclear. QUESTIONS/PURPOSES: (1) Which treatment relieves knee osteoarthritis pain better: PRP alone, exercise, or PRP combined with exercise? (2) Does PRP alone, exercise, or PRP combined with exercise yield better results in terms of the WOMAC score, performance on the 40-m fast-paced walk test and stair climbing test, and the SF-12 health-related quality of life score? METHODS: In this randomized, controlled, three-arm clinical trial, we recruited patients with mild-to-moderate (Kellgren-Lawrence Grade II or III) knee osteoarthritis with a minimum of 3 points on the 11-point numeric rating scale for pain. During the study period, 157 patients with a diagnosis of knee osteoarthritis were screened and 84 eligible volunteers were enrolled in the study. Patients were randomly allocated (1:1:1) into either the exercise group (28), PRP group (28), or PRP + exercise group (28). Follow-up proportions were similar between the groups (exercise: 89% [25], PRP: 86% [24], PRP + exercise: 89% [25]; p = 0.79). All patients were analyzed in an intention-to-treat manner. There were no between-group differences in age, gender, arthritis severity, and baseline clinical scores (pain, WOMAC, functional performance tests, and health-related quality of life). The exercise group underwent a 6-week structured program consisting of 12 supervised individual sessions focused on strengthening and functional exercises. Meanwhile, the PRP group received three weekly injections of fresh, leukocyte-poor PRP. The PRP + exercise group received a combined treatment with both interventions. The primary outcome was knee pain over 24 weeks, measured on an 11-point numeric rating scale for pain (ranging from 0 to 10, where 0 represents no pain and 10 represents the worst pain, with a minimum clinically important difference [MCID] of 2). The secondary outcome measures included the WOMAC index (ranging from 0 to 100, with lower scores indicating a lower level of disability and an MCID of 12), the durations of the 40-meter fast-paced walk test and stair climbing test, and the SF-12 health-related quality of life score. For the a priori sample size calculation, we used the numeric rating scale score for pain at 24 weeks as the primary outcome variable. The MCID for the numeric rating scale was deemed to be 2 points, with an estimated standard deviation of 2.4. Based on sample size calculations, a sample of 24 patients per group would provide 80% power to detect an effect of this size between the groups at the significance level of p = 0.05. RESULTS: We found no clinically important differences in improvements in pain-defined as >/= 2 points of 10-at 24 weeks when comparing exercise alone to PRP alone to PRP + exercise (1.9 +/- 0.7 versus 3.8 +/- 1.8 versus 1.4 +/- 0.6; mean difference between PRP + exercise group and exercise group -0.5 [95% confidence interval -1.2 to 0.4]; p = 0.69). Likewise, we found no differences in WOMAC scores at 24 weeks of follow-up when comparing exercise alone to PRP alone to PRP + exercise (10 +/- 9 versus 26 +/- 20 versus 7 +/- 6; mean difference between PRP + exercise group and exercise group -3 [95% CI -12 to -5]; p = 0.97). There were no differences in any of the other secondary outcome metrics among the PRP + exercise and exercise groups. CONCLUSION: PRP did not improve pain at 24 weeks of follow-up in patients with mild-to-moderate knee osteoarthritis compared with exercise alone. Moreover, exercise alone was clinically superior to PRP alone, considering function and the physical component of health-related quality of life. Despite the additional costs and endeavors related to PRP products, the combination of PRP and exercise did not differ from exercise alone. The results of this randomized controlled trial do not support the use of PRP injections in the treatment of patients diagnosed with mild-to-moderate knee osteoarthritis. Consequently, exercise alone is the recommended treatment for reducing pain and enhancing function throughout this timeframe. LEVEL OF EVIDENCE: Level I, therapeutic study. CI - Copyright (c) 2024 by the Association of Bone and Joint Surgeons. FAU - Karaborklu Argut, Sezen AU - Karaborklu Argut S AUID- ORCID: 0000-0002-7466-8105 AD - Department of Physiotherapy and Rehabilitation, Faculty of Health Services, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Celik, Derya AU - Celik D AD - Department of Physiotherapy and Rehabilitation, Faculty of Health Services, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Ergin, Omer Naci AU - Ergin ON AD - Department of Orthopedics and Traumatology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. FAU - Kilicoglu, Onder Ismet AU - Kilicoglu OI AD - Department of Orthopedics and Traumatology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20240206 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 SB - IM COIS- Each author certifies that there are no funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article related to the author or any immediate family members. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research(R) editors and board members are on file with the publication and can be viewed on request. EDAT- 2024/02/07 12:44 MHDA- 2024/02/07 12:44 CRDT- 2024/02/07 10:43 PHST- 2023/04/25 00:00 [received] PHST- 2024/01/08 00:00 [accepted] PHST- 2024/02/07 12:44 [medline] PHST- 2024/02/07 12:44 [pubmed] PHST- 2024/02/07 10:43 [entrez] AID - 00003086-990000000-01495 [pii] AID - 10.1097/CORR.0000000000002993 [doi] PST - aheadofprint SO - Clin Orthop Relat Res. 2024 Feb 6. doi: 10.1097/CORR.0000000000002993.